A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
AbstractBackground. The combination of galunisertib, a transforming growth factor (TGF)-β receptor (R)1 kinase inhibitor, and lomustine was found to have antit
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
21 February 2016
|
| In: |
Neuro-Oncology
Year: 2016, Jahrgang: 18, Heft: 8, Pages: 1146-1156 |
| ISSN: | 1523-5866 |
| DOI: | 10.1093/neuonc/now009 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1093/neuonc/now009 Verlag, Volltext: https://academic.oup.com/neuro-oncology/article/18/8/1146/1751761 
|
| Verfasserangaben: | Alba A. Brandes, Antoine F. Carpentier, Santosh Kesari, Juan M. Sepulveda-Sanchez, Helen R. Wheeler, Olivier Chinot, Lawrence Cher, Joachim P. Steinbach, David Capper, Pol Specenier, Jordi Rodon, Ann Cleverly, Claire Smith, Ivelina Gueorguieva, Colin Miles, Susan C. Guba, Durisala Desaiah, Michael M. Lahn, and Wolfgang Wick |
| Zusammenfassung: | AbstractBackground. The combination of galunisertib, a transforming growth factor (TGF)-β receptor (R)1 kinase inhibitor, and lomustine was found to have antit |
|---|---|
| Beschreibung: | Gesehen am 16.10.2018 |
| Beschreibung: | Online Resource |
| ISSN: | 1523-5866 |
| DOI: | 10.1093/neuonc/now009 |